Search the Newsreel

Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN

Janus Henderson Group PLC significantly reduced its stake in Enliven Therapeutics (NASDAQ:ELVN) by selling 1.66 million shares, retaining only 11,000 shares. Despite this, institutional investors still hold about 95.1% of the stock. Insider selling, including substantial sales by directors, also occurred, even as analysts …

Assenagon Asset Management S.A. Makes New Investment in Enliven Therapeutics, Inc. $ELVN

Assenagon Asset Management S.A. has acquired a new stake in Enliven Therapeutics (NASDAQ:ELVN), purchasing 306,574 shares valued at approximately $15.56 million. Other institutional investors have also adjusted their holdings in ELVN, while company insiders have recently sold shares totaling over $10 million. Analysts have …

Certain Options of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026.

Certain options of Enliven Therapeutics, Inc. are under a lock-up agreement that will end on August 11, 2026. This agreement restricts executive officers and directors from selling or otherwise disposing of shares of common stock and related securities for 61 days, starting from June …

LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70

LifeSci Capital has reiterated its Buy rating for Enliven Therapeutics (ELVN.US) and increased its target price to $70. This updated target price indicates a strong positive outlook from the firm regarding the company's future performance.

A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82

This article provides a quick look at current analyst ratings for Enliven Therapeutics (ELVN.US), noting a forecast price range of $68 to $82. It summarizes that the company has received 1 Buy rating and 1 Strong Buy rating from analysts.

Enliven Therapeutics director Mika Derynck sells $9.56m shares

Enliven Therapeutics director Mika Derynck sold 158,795 shares of company stock for approximately $9.

Enliven Therapeutics (ELVN) director exercises options, sells 158,795 shares

Enliven Therapeutics director Mika K. Derynck exercised stock options for 158,795 shares on August 4, 2026, at various exercise prices, then sold all 158,795 shares at a weighted average price of $60.2134 per share. These transactions were conducted as part of a Rule 10b5-1 …

Enliven Therapeutics, Inc. Stock 12‑Month Price Target Raised to $70.9, Implies 19% Upside

Enliven Therapeutics, Inc. (ELVN) has seen its average 12-month price target raised from $65.8 to $70.9 by 10 analysts, suggesting a 19% potential upside from its Aug. 5 closing price. The consensus rating from 11 covering analysts remains a "Buy," with no hold or …

FMR LLC and Abigail Johnson disclose 15% Enliven Therapeutics (ELVN) ownership

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G/A, disclosing a 15.0% beneficial ownership stake in Enliven Therapeutics Inc. (ELVN). This ownership amounts to 10,713,540.41 shares of common stock, with FMR LLC holding sole voting power over 10,704,808 shares and both …

Guggenheim lowers Enliven Therapeutics stock price target to $78 By Investing.com

Guggenheim has reduced its price target for Enliven Therapeutics (NASDAQ:ELVN) to $78 from $80, while maintaining a Buy rating. This adjustment follows the company's second-quarter 2026 results and an update on ELVN-001, which received FDA Fast Track Designation and is expected to begin Phase …

Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN

Enliven Therapeutics, Inc. 2Q 2026: Net loss $32.5M, EPS $(0.49) — 10-Q Summary

Enliven Therapeutics, Inc. reported a net loss of $32.5 million for the second quarter of 2026, an increase from $25.3 million in the prior year, with diluted loss per share remaining flat at $(0.49). The company continues to be pre-revenue, focusing on advancing its …

Enliven Therapeutics (NASDAQ:ELVN) Posts Earnings Results, Misses Expectations By $0.10 EPS

Enliven Therapeutics (ELVN) Expected to Post Earnings on Wednesday

Enliven Therapeutics (NASDAQ: ELVN) details planned stock sales via Jefferies

Enliven Therapeutics (NASDAQ: ELVN) has filed a Form 144 notice detailing proposed sales of common stock through Jefferies LLC. The filing specifies various stock option positions from 2022 to 2025, outlining the number of common shares to be sold. This transparency measure is intended …

95,253 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by DV Trading LLC

DV Trading LLC recently acquired 95,253 shares of Enliven Therapeutics (NASDAQ:ELVN), valued at approximately $3.7 million, making it their 16th largest holding. This acquisition comes as institutional investors collectively own 95.08% of the company, and Enliven Therapeutics reported better-than-expected quarterly earnings. Despite some insider …

Price to book forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN

The article displays the "Price to book forward" for Enliven Therapeutics, Inc. (NASDAQ: ELVN) on TradingView. It indicates that the market is currently closed with no trades, and the value for this financial metric is not provided within the snippet. The article also lists …

Trading Systems Reacting to (ELVN) Volatility

Enliven Therapeutics Inc. (NASDAQ: ELVN) is exhibiting neutral near-term sentiment amidst mid and long-term strength, characterized by a mid-channel oscillation pattern. AI models have developed distinct trading strategies for ELVN, including position, momentum breakout, and risk hedging, to optimize position sizing and minimize drawdown …

Enliven Therapeutics Inc (ELVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Enliven Therapeutics Inc (ELVN), detailing its stock performance, market capitalization, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on MACD, RSI, KDJ, ATR, CCI, Williams %R, TRIX, StochRSI, and moving …

ADAR1 Capital Management LLC Has $12.92 Million Holdings in Enliven Therapeutics, Inc. $ELVN

Enliven Therapeutics Inc (ELVN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Enliven Therapeutics Inc (ELVN), focusing on P/E, P/B, and P/CF ratios. However, it notes that relevant data for these metrics have not yet been disclosed by the company. The stock closed at $52.750, down 0.38%, with a …

Enliven Therapeutics Inc (ELVN) Cash Flow

This article provides a detailed cash flow statement for Enliven Therapeutics Inc (ELVN), presenting quarterly and annual data for operating, investing, and financing activities. It also defines various cash flow terms and offers answers to frequently asked questions regarding ELVN's financial performance. Investors can …

ELVN|Enliven Therapeutics Inc|Price:52.950|Chg%:+0.140

Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company focusing on developing small molecule inhibitors for cancer treatment, with two main product candidates, ELVN-001 and ELVN-002, targeting chronic myeloid leukemia and HER2 mutations, respectively. The article provides detailed company information, including its background, financial data, …

Enliven Therapeutics, Inc. $ELVN is Commodore Capital LP's 3rd Largest Position

Enliven Therapeutics, Inc. Revenue Breakdown – NASDAQ:ELVN

This page provides financial information for Enliven Therapeutics, Inc. (ELVN) on Nasdaq Stock Market through TradingView. It offers an overview of financials, including statements, statistics, dividends, earnings, and segments, but currently shows no trade data as the market is closed. The content emphasizes data …

Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67

Goldman Sachs has reaffirmed its Buy rating on Enliven Therapeutics (ELVN.US) and increased its price target to $67. This indicates a positive outlook from the investment bank regarding the company's future stock performance.

Enliven Therapeutics chief medical officer Collins sells $263k in shares

Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics, sold 5,000 shares of the company’s common stock for approximately $263,373 on July 17, 2026. These sales were based on a Rule 10b5-1 trading plan and occurred while the stock was near its 52-week high, …

Enliven Therapeutics (NASDAQ: ELVN) CFO sells 6,018 shares after option exercise

Enliven Therapeutics (NASDAQ: ELVN) CFO Benjamin Hohl reported exercising stock options for 1,072 shares and selling 6,018 common shares on July 17, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following these transactions, Hohl holds …

Enliven Therapeutics, Inc. (ELVN) CMO exercises options, sells 5,000 shares

Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised stock options for 5,000 shares at $2.48 each and subsequently sold all 5,000 shares in multiple transactions with weighted average prices ranging from $49.72 to $53.93. These transactions, executed on July 17, 2026, were performed …

Enliven Therapeutics Insider Sold Shares Worth $316,780, According to a Recent SEC Filing

An insider at Enliven Therapeutics (ELVN) recently sold shares valued at $316,780, as detailed in a new SEC filing. The company, a clinical-stage biopharmaceutical firm, is focused on developing small molecule therapeutics, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 inhibition. This …

ELVN Maintained by Goldman Sachs -- Price Target Raised to $67.0

Goldman Sachs has maintained a "Buy" rating for Enliven Therapeutics (ELVN) and raised its price target from $59.00 to $67.00, indicating increased confidence in the company's potential. Despite this optimistic analyst view, the company's GF Score™ is 28/100, suggesting challenges in profitability and growth, …

Enterprise value to EBIT forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN

This page provides financial data for Enliven Therapeutics, Inc. (NASDAQ: ELVN), specifically focusing on its enterprise value to EBIT forward. It is presented on TradingView, a platform offering market data and financial tools. The content includes general company information, stock market details, and links …

Price to earnings forward of Enliven Therapeutics, Inc. – BOATS:ELVN

This article provides "Price to earnings forward" data for Enliven Therapeutics, Inc. (ELVN), accessible through the TradingView platform. It highlights the stock's financial overview within the health technology and biotechnology sectors. The content primarily consists of navigation and platform information, with specific financial data …